| Schedule of geographic sales |
| |
|
Year Ended March 31, |
|
|
|
|
|
|
|
| |
|
2015 |
|
|
2014 |
|
|
$
Change |
|
|
%
Change |
|
| United States |
|
$ |
1,978,000 |
|
|
$ |
1,406,000 |
|
|
$ |
572,000 |
|
|
|
41% |
|
| Mexico |
|
|
5,053,000 |
|
|
|
3,758,000 |
|
|
|
1,295,000 |
|
|
|
34% |
|
| Europe and Rest of the World |
|
|
2,908,000 |
|
|
|
2,046,000 |
|
|
|
862,000 |
|
|
|
42% |
|
| |
|
|
9,939,000 |
|
|
|
7,210,000 |
|
|
|
2,729,000 |
|
|
|
38% |
|
| Product license fees and royalties |
|
|
3,056,000 |
|
|
|
5,513,000 |
|
|
|
(2,457,000 |
) |
|
|
(45% |
) |
| Total |
|
$ |
12,995,000 |
|
|
$ |
12,723,000 |
|
|
$ |
272,000 |
|
|
|
2% |
|
|
| Schedule of product license fees and royalties |
| |
|
Year Ended March 31, |
|
|
|
|
|
|
|
| |
|
2015 |
|
|
2014 |
|
|
$
Change |
|
|
%
Change |
|
| Exeltis/Quinnova |
|
$ |
437,000 |
|
|
$ |
807,000 |
|
|
$ |
(370,000 |
) |
|
|
(46% |
) |
| Onset/Precision |
|
|
– |
|
|
|
27,000 |
|
|
|
(27,000 |
) |
|
|
(100% |
) |
| Innovacyn |
|
|
1,120,000 |
|
|
|
3,100,000 |
|
|
|
(1,980,000 |
) |
|
|
(64% |
) |
| Laboratorios Sanfer and More Pharma |
|
|
1,499,000 |
|
|
|
1,501,000 |
|
|
|
(2,000 |
) |
|
|
0% |
|
| China distributor |
|
|
– |
|
|
|
78,000 |
|
|
|
(78,000 |
) |
|
|
(100% |
) |
| Total |
|
$ |
3,056,000 |
|
|
$ |
5,513,000 |
|
|
$ |
(2,457,000 |
) |
|
|
(45% |
) |
|